All Inquiries: 1+ 888-430-2221
OTCQB: CBBT   Cerebain Biotech Corp  


– Cerebain Biotech has received an invitation from the Polish National Center for Research and Development to present to a Poland-US Workshop

Dallas, TX September 23, 2015 – Cerebain Biotech (OTCQB: CBBT) today announced that the company has received an invitation from the Polish National Center for Research and Development to present to a Poland-US workshop on “Recommended improvements in practice and process to increase innovative advances in biomedicine and improved health care through IT applications”. The workshops will begin on October 6 and be held in Warsaw, Poland.

Leading the Cerebain team will be CEO Eric Clemons. Mr. Clemons will be presenting on innovative research the company is doing to address the Alzheimer’s epidemic. Cerebain has a patent-pending device that is implanted in the omentum, a protective layer that protects the abdominal organs. The device is designed to stimulate the omentum in patients with Alzheimer’s disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s disease.

While in Poland, Mr. Clemons will be meeting with international leaders in the neurology community. In addition, Mr. Clemons will be meeting with Private and Institutional testing centers to facilitate potential partnerships for testing endeavors.

About Cerebain Biotech Corp.

Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution.. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.

Forward Looking Statements

This news release contains certain “forward- looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

Download Press Release